Accepted Manuscript Association between Drug-Eluting Stent Type and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention William Chan, MB, BS, PhD Joan Ivanov, PhD Mark A. Kotowycz, MD, MBA Matthew Sibbald, MD Ross McGeoch, BM, BCh Noel Crooks, MD Rachael Hatton, MB, BS Douglas Ing, MD Paul Daly, MD Karen Mackie, RN Mark D. Osten, MD Peter H. Seidelin, MB Alan Barolet, MD, PhD Christopher B. Overgaard, MD, MSc Vladimír Džavík, MD PII:

S0828-282X(14)00320-1

DOI:

10.1016/j.cjca.2014.04.034

Reference:

CJCA 1210

To appear in:

Canadian Journal of Cardiology

Received Date: 30 December 2013 Revised Date:

7 April 2014

Accepted Date: 17 April 2014

Please cite this article as: Chan W, Ivanov J, Kotowycz MA, Sibbald M, McGeoch R, Crooks N, Hatton R, Ing D, Daly P, Mackie K, Osten MD, Seidelin PH, Barolet A, Overgaard CB, Džavík V, Association between Drug-Eluting Stent Type and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention, Canadian Journal of Cardiology (2014), doi: 10.1016/ j.cjca.2014.04.034. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Association between Drug-Eluting Stent Type and Clinical Outcomes in Patients

RI PT

With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

William Chan, MB, BS, PhD, Joan Ivanov, PhD, Mark A. Kotowycz, MD, MBA, Matthew Sibbald, MD, Ross McGeoch, BM, BCh, Noel Crooks, MD, Rachael Hatton, MB, BS,

SC

Douglas Ing, MD, Paul Daly, MD, Karen Mackie, RN, Mark D. Osten, MD, Peter H. Seidelin, MB, Alan Barolet, MD, PhD, Christopher B. Overgaard, MD, MSc, Vladimír

M AN U

Džavík, MD

Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Institute for Clinical Evaluative Sciences, Toronto, Ontario,

TE D

Canada

Drug-eluting stents in chronic kidney disease

EP

Word Count 4491

AC C

Corresponding author/address: Vladimír Džavík MD

6-246 EN Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada Fax: 416-340-3390 Email: [email protected] 1

ACCEPTED MANUSCRIPT

Brief Summary Patients with chronic kidney disease (CKD) are underrepresented in contemporary

RI PT

revascularization trials despite accounting for up to 40% of patients presenting to

cardiac catheterization. The comparative efficacy of first versus second generation drug-eluting stents in patients with CKD undergoing percutaneous coronary intervention

AC C

EP

TE D

M AN U

associated with similar 2-year clinical outcomes.

SC

is unknown. In this observational study, the use of first and second generation DES was

2

ACCEPTED MANUSCRIPT

Abstract Background: The comparative efficacy of first versus second generation drug-eluting

RI PT

stents (DES) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) is unknown.

Methods: A retrospective analysis of consecutive patients undergoing PCI at a tertiary PCI center from 2007-2011 was performed with linkage to administrative databases for

SC

long-term outcomes. CKD was defined as creatinine clearance